Neoadjuvant Pembrolizumab Improves High-Risk Early Breast Cancer Outcomes

New data from the Phase III KEYNOTE-756 clinical trial show that adding pembrolizumab immunotherapy to chemotherapy before and after surgery for high-risk breast cancer (which was estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative) resulted in better outcomes for patients regardless of their age or menopausal status.  The findings were presented at the 14th European Breast Cancer Conference by KEYNOTE-756 study co-author Heather McArthur, MD, MPH, Clinical Director of the Breast Cancer Program and Komen Distinguished Chair in Clinical Breast Research at the UT Southwestern Medical Center. She reported the findings at the Milan conference on behalf of her co-author Javier Cortés MD, Head of the International Breast Cancer Centre in Barcelona, Spain. After her talk in Milan, McArthur called into the OncTimesTalk Studio to talk about the findings with Peter Goodwin.